. 2021 Dec 20;145(4):1229–1241. doi: 10.1093/brain/awab465

Table 2.

Engineered next-generation antibody therapeutics in neurology: clinical trials

Next-gen mechanism	Exemplary mAb or Ab biologics	Target	Neurological indications	Clinical trials^a
Optimized half-life	Ravulizumab	Complement factor 5	MG	Phase 3, NCT03920293
	Ravulizumab	Complement factor 5	NMOSD	Phase 3, NCT04201262
	Satralizumab	IL-6 receptor	NMOSD	Phase 3, NCT02073279, NCT02028884
Enhanced Fc effector function/IgG stability	Ublituximab	CD20	RRMS	Phase 3, NCT03277248 Phase 2, NCT02738775
	Ublituximab	CD20	NMOSD	Phase 1, NCT02276963
	Inebilizumab	CD19	NMOSD	Phase 2/3, NCT02200770
	Rozanolixizumab	FcRn	MG,	Phase 3, NCT03971422 Phase 2, NCT03052751
	Rozanolixizumab	FcRn	CIDP	Phase 2, NCT03861481
Reduced Fc effector function	Aquaporumab	AQP4	NMOSD	Preclinical studies
	Crenezumab	Monomeric + aggregated amyloid-β	Alzheimer’s disease	Phase 2, NCT 01343966 Phase 3, NCT02670083, NCT03114657
	Eculizumab	Complement factor 5	MG,	Phase 3, NCT01997229
	Eculizumab	Complement factor 5	NMOSD	Phase 3, NCT01892345
	Eptinezumab	CGRP	Migraine	Phase 3 NCT02559895, NCT02974153
	Galcanezumab	CGRP	Migraine/cluster Headache	Phase 3, NCT02614261, NCT02614183, NCT02614196, NCT02397473
Superselective targets	Aducanumab	Aggregated amyloid-β	Alzheimer’s disease	Phase 3, NCT02484547, NCT02477800

CIDP = chronic inflammatory demyelinating polyneuropathy; MG = myasthenia gravis; RRMS = relapsing-remitting multiple sclerosis.

^{^a}

ClinicalTrials.gov.